MRD Dynamics During Maintenance for Improved Prognostication of 1280 Patients With Myeloma in the TOURMALINE-MM3 and -MM4 Trials
Recommended
MRD Dynamics During Maintenance for Improved Prognostication of 1280 Patients With Myeloma in the TOURMALINE-MM3 and -MM4 Trials
Conversion from MRD− to MRD+ or from MRD+ to MRD− status during ixazomib or placebo maintenance modulates the risk of disease progression.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->